DIAMICRON TABLET 80 mg

Land: Singapore

Språk: engelska

Källa: HSA (Health Sciences Authority)

Aktiva substanser:

GLICLAZIDE

Tillgänglig från:

SERVIER (S) PTE LTD

ATC-kod:

A10BB09

Dos:

80 mg

Läkemedelsform:

TABLET

Sammansättning:

GLICLAZIDE 80 mg

Administreringssätt:

ORAL

Receptbelagda typ:

Prescription Only

Tillverkad av:

LES LABORATOIRES SERVIER INDUSTRIE

Bemyndigande status:

ACTIVE

Tillstånd datum:

1990-04-20

Bipacksedel

Page 1 of 6 
Safety variation: drug interaction with clarithromycin +
new AE (Angioedema, TEN and SJS)

PRODUCT INFORMATION 
DIAMICRON 
INN: GLICLAZIDE 
COMPOSITION 

Gliclazide…………………………………………………………………………………………..…….80.00
mg 

Excipients q.s.f. one tablet 

INDICATIONS 

Non-insulin-dependent diabetes, in association with an adapted
diet, in cases where dietary measures 
alone provide inadequate control of blood glucose levels. 

DOSAGE AND METHOD OF ADMINISTRATION 

For adults only. 

As with all hypoglycaemic agents, the dosage must
be adapted to suit each individual case. 

In the case of transient disturbance of glucose
control, administration of the product for a short period 
of time may be sufficient in a patient
in whom the glucose balance is normally well maintained by 
dietary measures. 

*SUBJECTS UNDER THE AGE OF 65 YEARS 

Initial dose 

The recommended initial dose is 1 tablet per day. 

Dosage increments 

The dosage is usually
adjusted in increments of 1 tablet depending on the glycemic response. Each 
dosage increment should be separated by at least 14 days. 

Maintenance treatment 

The dosage varies from 1 to 3 tablets per day, 4
in exceptional cases. 

The standard dosage is 2 tablets per day, taken
as 2 daily doses. 

*HIGH RISK SUBJECTS 

Subjects over the age of 65 years 

- 
Begin the treatment with ½ tablet taken once a day. 
- 
This dosage may be progressively increased until satisfactory
glucose control is obtained in the 
patient, provided that an interval of at
least 14 days is maintained after each dosage increase and 
blood sugar levels are monitored closely. 

In other high-risk patients 

In patients who are undernourished or with a marked change in their
general state or whose calorie 
intake

Produktens egenskaper

Page 1 of 7
Safety variation: drug interaction with clarithromycin + new AE
(Angioedema, TEN and SJS)
PRODUCT INFORMATION
DIAMICRON
INN: GLICLAZIDE
COMPOSITION
Gliclazide…………………………………………………………………………………………....……………80.00
mg
Excipient with known effect: lactose.
Excipients q.s.f. one tablet
INDICATIONS
Non-insulin-dependent diabetes, in association with an adapted diet,
in cases where dietary measures alone provide
inadequate control of blood glucose levels.
DOSAGE AND METHOD OF ADMINISTRATION
For adults only.
As with all hypoglycaemic agents, the dosage must be adapted to suit
each individual case.
In the case of transient disturbance of glucose control,
administration of the product for a short period of time may be
sufficient in a patient in whom the glucose balance is normally well
maintained by dietary measures.
*SUBJECTS UNDER THE AGE OF 65 YEARS
Initial dose
The recommended initial dose is 1 tablet per day.
Dosage increments
The dosage is usually adjusted in increments of 1 tablet depending on
the glycemic response. Each dosage increment
should be separated by at least 14 days.
Maintenance treatment
The dosage varies from 1 to 3 tablets per day, 4 in exceptional cases.
The standard dosage is 2 tablets per day, taken as 2 daily doses.
*HIGH-RISK SUBJECTS
Subjects over the age of 65 years
-
Begin the treatment with ½ tablet taken once a day.
-
This dosage may be progressively increased until satisfactory glucose
control is obtained in the patient, provided
that an interval of at least 14 days is maintained after each dosage
increase and blood sugar levels are monitored
closely.
In other high-risk patients
Page 2 of 7
Safety variation: drug interaction with clarithromycin + new AE
(Angioedema, TEN and SJS)
In patients who are undernourished or with a marked change in their
general state or whose calorie intake is irregular, and
in patients with renal or hepatic insufficiency, treatment must be
initiated at the lowest dose and the guid